“So team's working really hard at this, and I'm not changing that target.”

In context

“ot a very strong brand in Similac, and you're seeing that. So -- and as I said, I think maybe to Josh's question at the beginning, if you look at the different segments, first of all, if you start with WIC and non-WIC. In the WIC segment, we're back to leadership position or back to our position we had before the recall. And that was because we focused a lot on that Q3, Q4 time in that segment. So I guess, long-winded to say yes. I mean, we're still on target for that to be able to get to the end of the year with our pre-recall market share. So -- and like I said, if you pull -- if you break out some of the different formulas because there's a lot of different SKU sets and different types of formulas. In some of them, we've already -- we're already back to where we were before recall. So team's working really hard at this, and I'm not changing that target. Operator: Our next question comes from Marie Thibault from BTIG. Marie Thibault: I wanted to ask a fairly high-level one here on the Diagnostics business. Now that COVID testing is sort of behind us, Core Lab was really strong this quarter. I just want to kind of get an update on the areas of investment and growth in Diagnostics testing today. The Alinity rollout, how that's progressing? And whatever else, in terms of tests or trends, we should be paying attention to now in Diagnostics? Robert Ford: Sure. I think we had a really, really good recovery here. As the health systems are opening up, you're seeing that routine testing come back. And like I said, it was pretty broad-based, U.S., Europe, Asia, Asia without China. I mean, it was pretty broad-based, Latin America. So that's worki”